Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Revvity IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs Recursion Pharmaceuticals Inc — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Revvity Inc is far larger — about 7.1× Recursion Pharmaceuticals Inc's market cap, and Revvity Inc pays a 0.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

RVTYRXRX
Market Cap
$12.91B$1.81B
Sector
TechnologyHealth
52-Week High
$117.75$6.79
52-Week Low
$82.26$2.84
Enterprise Value
$15.23B$1.33B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.

The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX